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Tbjective: Cryopreserved allograft tissue used in the Norwood procedure for infants
ith hypoplastic left heart syndrome causes profound immunologic sensitization,
hich may complicate future transplantation. Intravenous immunoglobulin has been
hown to reduce sensitization after it has developed, allowing successful transplan-
ation. The purpose of this pilot trial was to determine whether intravenous immu-
oglobulin given before and after the procedure could prevent sensitization to
ryopreserved allograft patches used in the initial repair of hypoplastic left heart
yndrome.
ethods: Intravenous immunoglobulin (2 g/kg) was given preoperatively, 3 weeks
ostoperatively, and 4 months postoperatively to 7 infants undergoing the Norwood
rocedure. Panel-reactive antibodies were measured with flow cytometry preoper-
tively and at 1, 4, 6, and 12 months postoperatively and compared with values from
contemporary cohort of 12 infants undergoing the Norwood procedure who did not
eceive intravenous immunoglobulin.
esults: The groups were well matched for length and weight at time of surgery.
ontrol infants were somewhat younger than the cohort receiving intravenous
mmunoglobulin (8  5 vs 17  14 days, P  .021). There were no differences in
ransfusion requirements. There was no difference in the degree of sensitization
etween control and intravenous immunoglobulin groups at 1 month (class I
anel-reactive antibodies 20%  30% vs 4%  9%, P  .443, class II panel-
eactive antibodies 17%  27% vs 20%  17%, P  .400), 4 months (class I
anel-reactive antibodies 62%  40% vs 73%  41%, P  .813, class II panel-
eactive antibodies 49%  42% vs 54%  41%, P  .706), and 12 months (class
panel-reactive antibodies 49%  42% vs 58%  39%, P  .686, class II
anel-reactive antibodies 44%  36% vs 49%  42%, P  .651).
onclusion: Despite studies showing intravenous immunoglobulin to reduce sensi-
ization, we were unable to demonstrate that intravenous immunoglobulin prevented
ensitization after exposure to allograft tissue in neonates undergoing congenital
ardiac surgery.
t has been well documented that previous sensitization complicates solid organ
transplantation. In cardiac transplantation, the presence of preformed anti-HLA
antibodies, measured as panel reactive antibody (PRA), is associated with
arlier and more frequent high-grade rejection,1,2 increased graft vasculopathy,3 and
ecreased survival.4 Importantly, Jacobs and colleagues5 recently reported that i
ediatric transplantation (median age 130 days), a PRA level greater than 10% was
ssociated with increased 30-day (25%) and long term (50%) mortality relative to
hose with a PRA level less than 10% (8% and 15%, respectively). Moreover,
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 6 1517
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Dlevated pretransplant PRA levels increase time on the
aiting list and complicate perioperative management at the
ime of transplantation.
Common causes of sensitization include previous trans-
lantation, pregnancy, and allogeneic blood products.6 In
ddition, several case series7-9 as well as a prospecti
ohort study from our institution10 have demonstrated tha
he cryopreserved allograft tissue used in congenital cardiac
urgery causes donor-specific sensitization, with class I and
I PRA values approaching 100%. This is of particular
oncern for certain groups of infants, such as those with
ypoplastic left heart syndrome (HLHS) undergoing the
orwood operation with cryopreserved allograft tissue. Al-
hough the results of this operation are improving,11 there
emains concern that many of these children will eventually
equire cardiac transplantation.
Reasonable alternatives to cryopreserved allograft tissue
re currently limited. Decellularization has been proposed
o reduce the immunogenicity of allograft, and work in our
aboratory has demonstrated that this does prevent sensiti-
ation in an animal model.12 Extensive testing, however, 
equired before this tissue is used in human beings. The use
f typical immunosuppressive agents, although effective13
s limited by long-term toxicity.14 Experience with kidney
nd cardiac transplantation has demonstrated that intrave-
ous immunoglobulin (IVIG) can produce clinically signif-
cant and sustained reductions in anti-HLA antibody titers in
ome patients who have been previously sensitized, in turn
llowing successful transplantation.15-19 Except for a recen
rial of prophylactic IVIG in patients with left ventricular
ssist devices,20 there is a paucity of information regard
he use of IVIG to prevent sensitization in previously un-
ensitized individuals. Thus the purpose of this novel pilot
tudy was to determine the efficacy of IVIG in preventing
he development of anti-HLA antibodies in children under-
oing repair of HLHS with allograft tissue.
aterials and Methods
tudy Design
VIG 10% (2g/kg) was administered 1 day preoperatively and 3
eeks and 4 months postoperatively in children undergoing sur-
ical repair of HLHS with cryopreserved allograft tissue. PRA
alues for class I and II antibodies were assessed with flow
ytometry preoperatively and at 1, 4, 6, and 12 months postoper-
tively and compared with a historical control group who had
ndergone repair of HLHS without IVIG. The study was approved
Abbreviations and Acronyms
HLHS hypoplastic left heart syndrome
IVIG  intravenous immunoglobulin
PRA  panel-reactive antibodyy the local institutional review board for human research, and e
518 The Journal of Thoracic and Cardiovascular Surgery ● Junritten consent was obtained from parents on behalf of the pa-
ients. This study was funded by the Stollery Children’s Hospital
oundation at the University of Alberta. The funding agency
layed no role in designing the study; in collecting, analyzing, and
nterpreting the data; in writing the report; or in making the
ecision to submit for publication.
tudy Cohort
even infants with HLHS undergoing first-stage palliation (Nor-
ood procedure) with a cryopreserved allograft pulmonary artery
atch were studied. Allograft tissue was provided by comprehen-
ive tissue centers at two Canadian University Hospitals (Univer-
ity of Alberta Hospital, Edmonton, Alberta, Canada, and Sick
ids Hospital, Toronto, Ontario, Canada).
ontrol Cohort
ata from 12 infants with HLHS who had previously undergone
he Norwood procedure with an allograft patch to reconstruct the
ortic arch 12 to 18 months before this study were reviewed. These
2 infants had been included in a previously reported stu10
hich had been approved by the local institutional review board.
o significant changes had been made in operative or periopera-
ive management during this short interval, and thus temporal bias
s presumed to be limited.
ntravenous Immunoglobulin
VIG 10% (Gammunex, caprylate and chromatography purified, 2
/kg) was administered 1 day preoperatively and 3 weeks and 4
onths postoperatively. Because of the volume-sensitive physiol-
gy of these children, IVIG was administered during hospitaliza-
ion: preoperative, 3 weeks postoperative, and at the time of the
idirectional cavopulmonary anastomosis procedure (4 months).
he first 2 doses are consistent with the 3-week half life of IVIG
nd previously described protocols15-18; the timing of the th
ose obviated a separate readmission specifically for the study.
VIG was infused according to established guidelines and given
ver the course of at least 8 hours.
ariables
reoperative variables to ensure similarity between the two groups
ncluded age, sex, length, and weight. Perioperative factors in-
luded durations of crossclamping and cardiopulmonary bypass,
se of hypothermic circulatory arrest, and blood product exposure
amount and type).
onor and Recipient HLA Typing
onor and recipient class I and II HLA typing was tested by
olecular methodology. Recipient DNA was purified from whole
lood with the QIAamp DNA Blood Mini Kit (QIAGEN Inc,
alencia, Calif). Donor DNA was purified from bone marrow or
cid-citrate-dextrose–stored blood. HLA A, B, and DR antigen
ypings were performed with the low-resolution Micro SSPTM
NA typing kit (One Lambda Inc, Canoga Park, Calif). DNA
ragments were separated by agarose gel electrophoresis. HLA
ntigens were determined through a combination of One Lambda
NA/LMT software analysis and manual interpretation of thelectrophoresis results.
e 2007
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DLA Antibody Analysis
creening for anti-HLA antibodies was performed with the Flow
RA Screening Test (One Lambda). Serum samples were analyzed
ccording to manufacturer recommendations. Test control serum
amples included a negative control sample from One Lambda
catalog No. FL-NC) and a positive control that was a 1:32 dilution
f a local positive pool made from many high-PRA patient sera. A
0-L mixture of class I and class II beads as well as control beads
as added to every tube. Patient serum samples (20 L) were
dded, and the tubes were incubated for 30 minutes. The tubes
ere washed twice, and 100 L diluted fluorescein isothiocyanate
onjugate (antihuman F[ab=]2) was added. A final wash step was
erformed, and the beads were analyzed with a FACSCalibur flow
ytometer (BD Biosciences, San Jose, Calif). Samples that tested
ositive for the presence of either class I or class II antibodies were
hen further tested for specificities with the FlowPRA Specific
ntibody Detection Test kit (One Lambda). Specificity analysis
as also performed with single-antigen beads if the PRA level was
reater than 60% (catalog Nos. FL2HD and FL1HD; One
ambda). In a few cases, antibody specificity for class II was also
etermined by enzyme-linked immunosorbent assay. The kit used
as Quickscreen Elisa (GTI Inc, Waukesha, Wis).
ata and Statistical Analyses
ll outcomes are expressed as mean  SD. Comparisons between
ontinuous data were made with the Mann–Whitney U test, and
omparisons between nominal data were made with 2 or Fisher
xact test as appropriate. All statistical analyses were performed
ith the Statistical Package for Social Sciences (version 13; SPSS
nc, Chicago, Ill).
esults
atient demographic characteristics are summarized in
able 1. Except for the control group being somew
ounger (8.2  4.8 vs 17.1  14.6 days; P  .021), the
ABLE 1. Patient demographic characteristics
ariable No IVIG IVIG used P value
o. 12 7
ge at surgery (d) 8.2 4.8 17.1  14.6 .021
ale sex (%) 75% 71% .999
ength (cm) 50.5 2.4 51.3  3.4 .608
eight (kg) 3.4 0.4 3.3  0.5 .734
rossclamp time (min) 42.6 27.7 31.1  17.9 .310
ardiopulmonary bypass
time (min)
127.2 59.7 123.4  40.0 .899
otal circulatory arrest
time (min)
28.0 10.6 18.4  10.9 .062
acked red blood cells
(units)
12.3 9.6 10.6  5.0 .966
latelets (units) 4.8 7.5 3.7  4.6 .999
resh-frozen plasma (units) 1.2 1.2 1.6  1.0 .565
ryoprecipitate (units) 3.8 4.3 3.9  3.2 .567
ll values are mean  SD. IVIG, Intravenous immunoglobulin.wo groups were well matched preoperatively. Most of 4
The Journal of Thoraciche discrepancy in age resulted from a single infant in the
VIG group who had surgery delayed until 49 days. Car-
iopulmonary bypass times were similar for the two groups
127.2  59.7 vs 123.4  40.0 minutes, P  .899 ), but the
VIG group required a marginally shorter circulatory arrest
ime (28.0  10.6 vs 18.4  10.9 minutes, P  .062). Both
roups required similar amounts of blood products periop-
ratively, including packed red blood cells (12.3  9.6 vs
0.6  5.0 units, P  .966), platelets (4.8  7.5 vs 3.7 
.6 units, P  .999), fresh-frozen plasma (1.2  1.2 vs
.6  1.0 units, P  .565), and cryoprecipitate (3.8  4.3
s 3.9  3.2 units; P  .567).
The preoperative dose of IVIG was consistently given at
.0 2.4 days before surgery, the second dose at 22.4 2.8
ays after surgery, and the third dose during hospitalization
or the bidirectional cavopulmonary anastomosis procedure
141.3  28.3 days after initial surgery). IVIG was admin-
stered without adverse events.
Relative to control infants who did not receive IVIG,
here were no significant differences in class I or II PRA
alues for those who did receive IVIG (Figures 1 an
reoperatively (before the initial dose of IVIG), there were
inor elevations in both class I and II antibodies, most
ikely reflecting maternally transmitted (passive) antibodies.
ne month postoperatively (1 week after the second dose
f IVIG), there was evidence of a humoral immune re-
ponse, with modest elevations in class I (19.7%  30.1%
s 4.5%  9.0%, P  .443) and class II (17.1%  27.5%
s 20.0%  17.1%, P  .400) PRA for the control and
VIG groups, respectively. Similarly, no significant differ-
nces were noted for the control and IVIG groups at 4
onths (class I PRA 61.9%  39.9% vs 72.7%  41.1%,
 .813, class II PRA 49.3% 41.9% vs 53.8% 40.5%,
 .706) and 12 months (class I PRA 49%  42% vs
8%  39%, P .686, class II PRA 44% 36% vs 49% 
igure 1. Class I panel-reactive antibody (PRA) levels: preoper-
tive and 1, 4, and 12 months postoperatively. IVIG, Intravenous
mmunoglobulin.2%, P  .651). A more detailed review of the individual
and Cardiovascular Surgery ● Volume 133, Number 6 1519
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DRA values at 4 months for recipients of IVIG revealed
hose with no response to IVIG, with PRA levels approach-
ng 100%, and others with responses, with PRA levels
anging from 0% to 29% (Figure 3). Moreover, in a
atients, PRA appeared to decline after 4 months. HLA
yping of donor and recipient confirmed that responders
ere mismatched for both class I and II antigens (Tab
iscussion
he Norwood operation has become the accepted standard
f care for neonates with HLHS. Although alternatives have
een reported, a cryopreserved allograft pulmonary artery
atch has long been the preferred material to reconstruct the
iminutive aorta in these infants. Despite previous beliefs
hat this tissue was immunoprivileged, recent investigations
y our group and others have provided evidence that allo-
raft tissues stimulate alloreactive immune responses. Hu-
an21 and animal22 studies have provided evidence for 
ntense T-lymphocyte response. In addition, others have
emonstrated a humoral immune response in recipients of
llograft tissue. The published frequency of development of
nti-HLA antibodies (PRA) to cardiac valve allografts
anges from 78%8 to 100%,9 with PRA levels approachin
2%.7 In a prospective cohort study at our institution 
ompared PRA in infants receiving allograft tissue during
he Norwood procedure with that in infants undergoing an
rterial switch procedure and not receiving allograft tissue,
e clearly demonstrated that children who received allo-
raft tissue had PRA develop approaching 100%.10 More-
ver, a substantial proportion of the antibodies were donor
pecific.
Although the results of the Norwood operation for HLHS
re steadily improving,11 it is possible that many of th
hildren will eventually require cardiac transplantation.
here is concern regarding the impact the previously
igure 2. Class II panel-reactive antibody (PRA) levels: preoper-
tive and 1, 4, and 12 months postoperatively. IVIG, Intravenous
mmunoglobulin.escribed sensitization will have on successful transplan- g
520 The Journal of Thoracic and Cardiovascular Surgery ● Jun).
ation. It has been documented that the presence of anti-
odies in the serum of the allograft recipient significantly
ncreases the risk of early allograft failure and poorer patient
urvival as a result of humoral rejection.1-5 Notable is 
eview by the United Network of Organ Sharing Registry of
4,535 heart transplants performed between 1987 and 1996;
t demonstrated that an elevated PRA at transplantation
ignificantly increased the relative risk of graft failure (P 
0001).4 Moreover, a PRA value greater than 60% 
ound to be associated with a 2.242 relative risk of graft
ailure. Similar findings have recently been reported in
ediatric heart transplantation.5 Consequently, the presenc
f anti-HLA antibodies limits the ability to find a T-cell
rossmatch–negative donor. Waiting times for a suitable
llograft are thus considerably longer, and the mortality
hilst waiting for a donor is high.
Despite extensive investigation, suitable alternatives to
llograft tissue have yet to be identified. Glutaraldehyde-
reated xenograft tissue tends to undergo rapid calcification
nd fail even more rapidly than allograft tissue, especially in
hildren. Moreover, no material comes close to the handling
roperties of allograft tissue, for instance when attempting
o reconstruct the aortic arch of a newborn infant. This latter
oncern is particularly true of synthetic material (eg, poly-
etrafluoroethylene and Dacron polyester fabric). Thus allo-
raft tissue continues to play an essential role in congenital
ardiac surgery. Numerous potential methods exist or are
eing investigated to reduce the immunogenicity of allo-
igure 3. Line plot of panel-reactive antibody (PRA) in infants
eceiving intravenous immunoglobulin.raft tissues. Tissue matching (donor-recipient HLA match-
e 2007
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Dng) would be a complex and expensive process. Decellu-
arization techniques are currently being explored in a
umber of laboratories, including our own12; however, thei
se requires extensive additional investigation.
Altering the host with typical immunosuppressive agents
eg, cyclosporine [INN ciclosporin], mycophenolate mofetil) is
ffective but is limited by these agents’ well-documented
hort- and long-term toxicities.14 A recent study by Shadd
nd associates13 demonstrated that mycophenolate mofet
600 mg/m2 per dose) twice daily for 3 months substantially
educes anti–class I (but not anti–class II) antibodies. One
atient withdrew after 2 weeks because of a sinus infection
hat was successfully treated with oral antibiotics, and 3
atients had a transient adverse effect of postoperative vom-
ting. Of note, this study used leukocyte-depleted blood
roducts, (both filtered and irradiated products) which may
ave impacted the degree of antibody response. Blood in
ur study was not routinely irradiated. Long-term use of
hese agents in children is difficult to justify, despite
fficacy.
IVIG is an alternative immunomodulatory agent demon-
trated to be safe. Experience with kidney and cardiac
ransplantation has demonstrated that this agent can produce
linically significant and sustained reductions in anti-HLA
ntibody titers in individuals who have been previously
ensitized, in turn allowing successful transplantation.15-19
 recent article by Glotz and colleagues18 reported the
uccessful desensitization in 13 of 15 patients (87%) in a
ilot trial with 3 monthly courses of 2 g/kg body weight
VIG. These 13 patients underwent immediate kidney trans-
lantation, with loss of only 1 of the kidneys to rejection. In
ABLE 2. Donor–recipient HLA mismatch
ase
Antigen mismatches* PRA at 4 mo
Class I Class II Class I (%) Class II (%)
1 A1 A24 B8 DR17 DR15 DR52 0 0
2 A3 B7 B62 DR11 DR16 DR51
DR52
98 76
3 A1 A30
B18 B63
DR1 DR13 96 29
4 NA NA 98 93
5 A2 B44
B62
DR4 98 98
6 NA NA 46 27
7† A32 B27 DR17 DR103 NA NA
RA, Panel-reactive antibody; NA, not applicable (donor or recipient typing
ecipient was not matched. †Withdrew from study before 4 months.ddition, the National Institutes of Health–sponsored IG02 s
The Journal of Thoracicrial randomly assigned 101 adult patients with end-stage
enal disease who had a PRA level greater than 50% to receive
ither IVIG (2g/kg monthly for 4 months) or placeb16
VIG therapy was associated with a modest improvement in
ransplantation rates (35% vs 20%, P  .069), reduced time
o transplantation (P .05), and decreased mortality (8% vs
6%, P  .22). The numerous mechanisms by which IVIG
s thought to exerts its immunomodulatory effects are be-
ond the scope of this article and have been summarized in
 number of recent reviews.23-26
In this study we tested the hypothesis that IVIG could
educe development of sensitization in previously unsensi-
ized individuals. Despite the extensive aforementioned
ocumentation of the effectiveness of IVIG in reducing
lloreactive antibody levels, this pilot study did not demon-
trate any benefit in giving IVIG before and after exposure
o allogeneic material. In this study, there was no difference
etween PRA values of patients receiving IVIG and those of
atients not receiving IVIG. The lack of response to IVIG
ay be dose related; however, we used a dose (2 g/kg) that
s standard in most successful desensitization protocols,
ncluding the National Institutes of Health IG02 trial.15-18
ur findings are consistent with a recent trial of IVIG to
revent sensitization in ventricular assist device recipi-
nts.20 In that trial, IVIG (10 g/d for 3 days) had no 
n either the mean PRA or the number of individuals
ecoming sensitized during mechanical support. It is impor-
ant to note that our study did not use additional desensiti-
ation techniques, including plasmapheresis and other im-
unosuppressive agents as noted in many previous case
Antibody specificities Donor-specific antibodies
NA
A3 A30 A68 A11 A34 A24 A32 A33
31 A23 A13 B35 B62 B45 B60 B44
49 B57 B7 B8 B55 B65 DR11DR13
R14 DR15 DR16 DR17 DR18 DR52
R4 DR5 DR6 DR8 DR9
A3 B7 B62 DR16 DR11 DR52
A3 A29 A30 A26 A11 A32 A31 B18
62 B57 B52 B8 DR1 DR103 DR16
A1 A30 B18 DR1
3 A24 A29 B49 B13 B45 B60 B44
57 B7 B8 B55 DR4 DR7 DR13
NA
2 A68 A25 A26 A34 A32 A23 A24
29 A11 B 49 B51 B52 B62 B35
57 B44 B45 B65
A2, B44, B62
A26 A66 DR1 DR10 NA
NA
not performed). *Antigen mismatches represent donor antigens at whichNA
A2
A
B
D
D
A1
B
A 2
B
A1A
A
B
A25
NA
waseries.
and Cardiovascular Surgery ● Volume 133, Number 6 1521
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DThe dosing regimen took into consideration the half-life
f IVIG (3 weeks) and the need to administer the agent under
losely monitored conditions in highly volume-sensitive
nfants. This led to the choice of dosing times: preoperative
before exposure to allograft tissue), 3 weeks (infant still in
ospital), and 4 months (infant returns for bidirectional
avopulmonary anastomosis). The Stollery Children’s Hos-
ital is a tertiary referral center for pediatric heart surgery
nd receives patients from an extremely large geographic
rea (Western Canada); thus having infants return for more
requent dosing would not have been possible and would
ave limited enrollment. Consequently, the major limi-
ation of this study was the need to administer the IVIG
hile the patient was in the hospital and the resultant
nability to administer IVIG at 2 and 3 months after surgery.
his period is the critical window of antibody development,
hen the child is most likely acquiring memory B cells to
he allograft tissue. Thus in effect we were only testing the
fficacy of the first two doses of IVIG, with the impact of
he third dose at 4 months questionable. Regardless, Glotz
nd colleagues18 achieved a 50% reduction in PRA wit
onthly courses of 2 g/kg IVIG. John and cowork17
eported a mean reduction of 33% in anti-HLA class I
eactivity within 1 week of 2 g/kg IVIG. Moreover, Glotz
nd colleagues18 demonstrated that the maximal reductio
n alloreactivity occurs within 1 week of IVIG therapy and
hat sequential doses of IVIG did not have an additive effect
n reduction of circulating anti-HLA class I IgG antibodies.
imilarly, in the IG02 trial, in which IVIG was administered
t 2 g/kg monthly for 4 months, most of the reduction in
RA was seen within the first month.16 The findings o
hese studies contrast sharply with ours, in which there was
o response to IVIG seen within the first month of therapy.
There are a number of limitations to this study. Small
ample size limits statistical calculations. Review of the
catterplots and comparison with control patients who did
ot receive IVIG, however, demonstrates a lack of re-
ponse to IVIG. There is also increasing discussion that
he PRA may not be the most suitable test to determine
ensitivity.27 Antibody specificity and titers may be
ore sensitive method to determine the degree of sensiti-
ation. Alternatively, use of less sensitive methods than
ow PRA, such as complement-dependent cytotoxicity and
ntiglobulin-enhanced complement-dependent cytotoxicity,
ight have helped determine the impact on antibody titers.
f the antibodies we detect after IVIG therapy are low titer,
hey may be more amenable to subsequent modulation
herapies at the time of transplantation. Additionally, longer
ollow-up may reveal a delayed effect of IVIG after 12
onths. Finally, if heart transplantation is required in the
uture, determination of crossmatch results may be revealing.
In conclusion, this novel study was unable to demon-trate that IVIG prevents sensitization after exposure to
522 The Journal of Thoracic and Cardiovascular Surgery ● Junllograft tissue in neonates undergoing congenital cardiac
urgery. These findings were seen despite studies in adults,
hich have demonstrated that high-dose (2 g/kg) IVIG
educes sensitization. The ultimate test will be long-term
ollow-up and determination of whether early treatment
ith IVIG improves future transplantability.
We gratefully acknowledge Lea Legge, Pam Wiebe, Dr Mi-
hael Tyrrell, Michelle Loeffler, Patty Knox, Kelly Dealy, and Dr
eorge Sandor for their assistance in following up the study
articipants at the referring hospitals.
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